Human Intestinal Colonoid infected with Enteroaggregative E. coli.
Lab of Dr. Anthony Maresso, Department of Molecular Virology & Microbiology, Baylor College of Medicine
Coronavirus Initiatives
Baylor College of Medicine faculty are actively engaged with industry leaders to accelerate efforts towards understanding, tracking and fighting the current COVID-19 pandemic and preparing for future outbreaks. As we aim to stimulate global recovery, we encourage you to partner with us if your Coronavirus/COVID-19 research in vaccine development, diagnostics and testing, public health/surveillance, or another platform could advance with an industry partnership. Contact: bcmventures@bcm.edu
We Believe the Difference between Brilliant Ideas and Innovation Lies in Smart Execution
For visionary faculty members with novel ideas, and progressive businesses in-need of new technology, Baylor College of Medicine Ventures (BCMV) provides a springboard for university knowledge to reach industry and impact lives.
We’ve built a dedicated Ventures hub, where our passionate team of commercial experts provide infrastructure, cultivate ideas and create novel and ambitious collaborative ventures to drive impact.
Looking to collaborate? Reach our team: bcmventures@bcm.edu
Leadership and Team
View a listing of the BCM Ventures leadership and team members.
Industry and Investors
Discover how our innovative, collaborative and entrepreneurial environment can assist you in fulfilling your mission. Find available technologies and learn about opportunities for you at Baylor College of Medicine.
Faculty Innovators
BCMV provides an ecosystem that empowers innovative faculty members to advance their inventions through commercial activities. Find out how our team can support your journey.
Research Collaboration to Focus on Neonatal Epilepsy
Knopp Biosciences has entered a research collaboration with Baylor College of Medicine to develop new treatments for KCNQ2 neonatal encephalopathy.
Clinical Trial Updates
Marker Therapeutics releases clinical updates in three Baylor College of Medicine-sponsored Phase I/II clinical trials using its MultiTAA T cell therapies, LAPP and MAPP.
